To assess the efficacy and safety of parathyroid hormone (PTH) analogs compared to conventional therapy for Hypoparathyroidism (HypoPTH) and its impact on patients’ health-related quality of life (HRQoL).
Approach:
Data Sources: Systematic search of PubMed, Web of Science, Embase, and Cochrane Library until February 28, 2026.
Key Findings:
PTH analogs showed no significant difference in serum calcium (MD = -0.02 mmol/L; 95% CI, -0.14 to 0.11 mmol/L) and serum phosphorus (MD = 0.08 mmol/L; 95% CI, -0.05 to 0.20 mmol/L) compared to conventional therapy.
PTH analogs decreased serum 25(OH) vitamin D but increased 1,25(OH)2 vitamin D and estimated glomerular filtration rate (eGFR).
PTH analogs significantly improved HRQoL as measured by the SF-36 Health Survey Questionnaire (MD = -7.35; 95% CI, -8.37 to -6.33).
Interpretation:
PTH analogs provide comparable control of serum calcium and phosphorus levels to conventional therapy, with potential benefits in regulating vitamin D and maintaining eGFR.
Limitations:
Limited data on the long-term effects of PTH analogs.
Variability in study designs and patient populations across included studies.
Conclusion:
PTH analog therapy has comparable efficacy in managing serum calcium and phosphorus levels in patients with HypoPTH.
